Use of autologous platelet-rich plasma in knee osteoarthritis symptomatic treatment

Among the conservative methods of treatment of osteoarthritis the use of plasma enriched with soluble platelet factors /platelet-rich plasma (PORFT/PRP) is becoming increasingly attractive.

The aim of the study was to determine the tolerability and effect of intra-articular administration of standardized autologous PRP on patients with knee osteoarthritis status based on the survey results. Patients with knee osteoarthritis (OA) received standard drug therapy (n = 19) or additionally standardized autologous platelet-rich plasma (PRP) (n = 21). Intraarticular injection of 6 ml of PRP was carried out three times every two weeks. The administration safety was assessed. Patients were questioned with an assessment of VAS and WOMAC scales in 2 weeks, 1 month and 3 months after starting the treatment. It was shown that three-time intra-articular administration of standardized autologous PRP was safe for a patient. At the same time, the pain syndrome decreased (VAS score) and the knee joint function improved (WOMAC score) after 1 and 3 months. All indicators were significantly better compared to the control group. We concluded that standardized autologous PORFT with three intra-articular injections is safe and has an analgesic effect and preserves the function of the knee joint already within 1–3 months of observation.

1. Karateev A. E., Lila A. M. Osteoarthritis: current clinical concept and some promising therapeutic approaches. Nauchno-prakticheskaya revmatologiya [Rheumatology science and practice], 2018, vol. 56, no. 1, pp. 70–81 (in Russian).

2. Filardo G., Previtali D., Napoli F., Candrian C., Zaffagnini S., Grassi A. PRP injections for the treatment of knee osteoarthritis: a meta-analysis of randomized controlled trials. Cartilage, 2021, vol. 13, suppl. 1, pp. 364S–375S. https://doi.org/10.1177/1947603520931170

3. Costa L. A. V., Lenza M., Irrgang J. J., Fu F. H., Ferretini M. How does platelet-rich plasma compare clinically to other therapies in the treatment of knee osteoarthritis? A systemic review and meta-analysis. American Journal of Sports Medicine, 2022, vol. 51, no. 4, pp. 1074–1086. https://doi.org/10.1177/03635465211062243

4. Kim J.-H., Park Y.-B., Ha C.-W. Are leukocyte-poor or multiple injections of platelet-rich plasma more effective than hyaluronic acid for knee osteoarthritis? A systemic review and meta-analysis of randomized controlled trials. Archives of Orthopaedic and Trauma Surgery, 2022, vol. 143, no. 7, pp. 3879–3897. https://doi.org/10.1007/s00402-022-04637-5

5. Potapnev M. P., Zagorodnyi G. M., Krivenko S. I., Bogdan V. G., Svirskii A. O., Yasyukevich A. S., Asaevich V. I., Bukach D. V., Eismont O. L. Modern aspects of the use of plasma enriched in soluble platelet factors in the treatment of injuries and diseases of the musculoskeletal system. Sportivnaya meditsina: nauka i praktika [Sports medicine: research and practice], 2019, vol. 9, no. 4, pp. 33–45 (in Russian).

6. Andia I., Maffulli N. Platelet-rich plasma for managing pain and inflammation in osteoarthritis. Nature Reviews Rheumatology, 2013, vol. 9, pp. 721–730. https://doi.org/10.1038/nrrheum.2013.141

7. Cook C. S., Smith P. A. Clinical update: why PRP should be your first choice for injection therapy in treating osteoarthritis of the knee. Current Reviews in Musculoskeletal Medicine, 2018, vol. 11, pp. 583–592. https://doi.org/10.1007/s12178-018-9524-x

8. Vilchez-Cavazos F., Blazquez-Saldana J., Gamboa-Alonso A., Pena-Martinez V., Acosta-Olivo C., Sanchez-Garcia A., Simental-Mendia M. The use of platelet-rich plasma in studies with early knee osteoarthritis versus advanced stages of the disease: a systematic review and meta-analysis of 31 randomized clinical trials. Archives of Orthopaedic and Trauma Surgery, 2022, vol. 143, vol. 3, pp. 1393–1408. https://doi.org/10.1007/s00402-021-04304-1

9. Moretti L., Maccagnano G., Coviello M., Cassano G. D., Franchini A., Laneve A., Moretti B. Platelet rich plasma injections for knee osteoarthritis treatment: a prospective clinical study. Journal of Clinical Medicine, 2022, vol. 11, no. 9, art. 2640. https://doi.org/10.3390/jcm11092640

10. Potapnev M. P., Krivenko S. I., Bogdan V. G., Kosmacheva S. M., Shlyaga O. L., Karpenko F. N. Platelet-rich derived plasma: manufacture and medical application. Zdravookhranenie [Healthcare], 2018, no. 10, pp. 38–44 (in Russian).

11. Potapnev M. P., Kondratenko G. G., Troyanov A. A., Karman A. D., Krivenko S. I., Nazarova E. A., Levandovskaya O. V. Blood autodonation possibilities for platelet-rich plasma preparation to treat diabetic foot ulcers. Meditsinskii zhurnal [Medical journal], 2016, no. 2, pp. 91–94 (in Russian).

12. Andia I., Maffulli N. A contemporary view of platelet-rich plasma therapies: moving toward refined clinical protocols and precise indications. Regenerative Medicine, 2018, vol. 13, no. 6, pp. 717–728. https://doi.org/10.2217/rme-2018-0042